(NASDAQ: DWTX) Dogwood Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.63%.
Dogwood Therapeutics's earnings in 2026 is -$36,041,288.On average, 4 Wall Street analysts forecast DWTX's earnings for 2026 to be -$20,283,356, with the lowest DWTX earnings forecast at -$20,320,748, and the highest DWTX earnings forecast at -$19,987,621. On average, 4 Wall Street analysts forecast DWTX's earnings for 2027 to be -$25,830,941, with the lowest DWTX earnings forecast at -$29,648,305, and the highest DWTX earnings forecast at -$21,415,308.
In 2028, DWTX is forecast to generate -$25,657,579 in earnings, with the lowest earnings forecast at -$31,313,940 and the highest earnings forecast at -$19,273,778.